Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

PCI Announces Capital Investment in Rockford Facilities

Published: Wednesday, July 10, 2013
Last Updated: Wednesday, July 10, 2013
Bookmark and Share
Leading pharmaceutical packaging firm investing in support of business growth.

Packaging Coordinators Inc (PCI) has announced further investment in its Rockford facilities in support of business growth and expansion.

The company acquired AndersonBrecon Inc. in May of this year and is adding additional equipment capacity and facilities infrastructure through capital investment, as well as hiring in support of business growth.

The company provides packaging services for pharmaceutical and healthcare products, working with leading Pharmaceutical and Biotech companies to bring lifesaving medicines to patients.

PCI operates 9 facilities in the greater Rockford, Illinois area totaling over 1 million square feet and employing over 1,300 highly trained associates.

PCI is owned by an entity formed by affiliates of lead investor Frazier Healthcare, a leading provider of growth equity and venture capital to high growth and emerging healthcare service and Biotech companies.

Continued Growth and Expansion
PCI’s Rockford location is experiencing its fourth straight year of significant growth. The company is experiencing substantial growth in 2013, which is anticipated to continue in 2014 and beyond.

In support of this growth, PCI has hired approximately 160 associates since January of 2012. Positions added include hourly, skilled labor, as well as management.

In addition to hiring, the company is looking to support new business by expanding its machine capacity, warehousing, and facilities infrastructure. PCI has added multiple blister packaging and bottling lines to meet increased demand in Ethical (prescription) and Over-the-Counter pharmaceutical markets and plans additional investment in this area.

The company is also investing in support of growth markets including commercial Biotech medicines and Clinical (Investigational) medicines.

Capital investments include expansion of on-site refrigerated Cold Chain storage capacity at 2 – 8° Celsius, -20° Celsius, and -80° Celsius.

A History Of Investment
The company opened a stand-alone potent compound packaging facility in 2010 and a new Clinical (Investigational) medicines packaging facility in 2011.

PCI’s largest Rockford facility, located at the Greater Rockford Industrial Park, was most recently expanded in 2008 and comprises over 720,000 square feet.

PCI’s North American and European sites feature state-of-the-art packaging facilities and cutting edge technologies, supporting very recognizable brands in the global healthcare market.

The company packages medicines destined for patients spanning over 100 countries across the globe. PCI’s headquarters in Philadelphia, PA employs approximately 475 associates.

A facility in Woodstock, IL employs approximately 125 additional associates. PCI’s domestic locations are complemented by four packaging sites in Wales, which currently employ approximately 300 associates, mainly in support of pharmaceutical products for the European region.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PCI Announces Definitive Agreement to Acquire Penn Pharma
PCI’s expands service offering with acquisition of Penn Pharma.
Thursday, July 31, 2014
Peter Belden Named General Manager of PCI Rockford Facilities
Belden returns to PCI North America to manage Rockford, IL operations.
Monday, September 02, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos